About Us

About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.

By: via Business Wire

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced the passing of its beloved and respected longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.

“The entire Enanta team mourns the loss of Paul, our colleague and friend,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “Since joining the Company more than two decades ago, Paul’s leadership and generosity of spirit have been at the core of Enanta. Paul’s dedication to the Company was complete and steadfast. He carried himself with humility, led with compassion, and inspired trust, and his relationships were authentic, rich, and fun.”

Dr. Luly added, “Paul joined Enanta in September 2003 and established the finance department, bringing critical expertise that shaped the Company’s growth and success. He led Enanta’s Initial Public Offering in 2013 and was instrumental in advancing the Company’s early partnerships, including the strategic 2006 research and development collaboration with Abbott, now AbbVie, that resulted in commercialization of VIEKIRA PAK® and MAVYRET®/MAVIRET® – two medications for the treatment of chronic hepatitis C virus infection that have cured more than one million patients globally. Paul’s legacy will forever be woven into the fabric of Enanta, and his friendship will be missed by all of us. On behalf of Enanta, and the Board of Directors, we extend our deepest, heartfelt condolences to his family and friends.”

Paul’s successful career spanned almost 50 years. Prior to joining Enanta, he was Senior Vice President and Chief Financial Officer of Essential Therapeutics. Before that, Paul was the Chief Financial Officer and Vice President of Administration at GelTex Pharmaceuticals, Inc., a publicly held biotechnology company that was acquired by Genzyme Corporation in December 2000. Paul also served as Chief Financial Officer of Marshall Contractors, a construction management firm specializing in the pharmaceutical, biotechnology and semiconductor industries. Earlier in his career, Paul was employed with Deloitte & Touche LLP, a public accounting firm, where he served as Audit Partner. He graduated from Boston College. He also graduated from Xaverian Brothers High School where he served proudly on its board for 12 years. Paul also dedicated his time as a board member of Norwood Hospital and Big Brothers Big Sisters of Boston, demonstrating his commitment to service.

As previously announced, Harry R. Trout, III, and Kathleen S. Capps, CPA, have been appointed as the Company’s principal financial officer and principal accounting officer, respectively, in each case on an interim basis.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.

The entire Enanta team mourns the loss of Paul, our colleague and friend.

Contacts

More News

View More
Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
Via MarketBeat
Topics Economy
Tickers HIMS
After the Fed's Rate Cut, PNC Could See a Mortgage Refinance Boom
Via MarketBeat
Topics Economy
Tickers PNC
AIRO Group's Pullback: An Undervalued Growth Opportunity?
Via MarketBeat
Topics Supply Chain
Tickers AIRO
Caterpillar Stock Hits All-Time High—Is There More Room to Run?
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
Tickers CAT
Berkshire-Backed Lennar Slides After Weak Q3 Earnings
Via MarketBeat
Topics ETFs
Tickers BRK-A BRK-B LEN
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.